Adalvo extends its strategic collaboration with Bioventure, the subsidiary of Healthcare Division of Yas Holding, within the MENA region

Adalvo and STADA extend their strategic partnership

Zentiva extends its collaboration with Adalvo and strengthens its offering in Respiratory, CNS and Dermatology

Adalvo and Frontier Biopharma/Zdravlje Sign Licensing & Supply Agreement for Central & Eastern Europe

Adalvo signs licensing deal with MS Pharma for Solifenacin + Tamsulosin

Adalvo and Aristo Pharma sign licensing & supply agreement to commercialise a basket of products

Adalvo and Actor Pharmaceuticals Sign Exclusive Licensing Agreement to Commercialise a Basket of Products in the Australian Market

Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets

Adalvo advances in the pain domain, offering an extensive portfolio of pain management medication

Adalvo Announces successful DCP closure for Fulvestrant pre-filled injection

Adalvo acquires its first branded product, Onsolis®

Adalvo announces DCP approval for Dimethyl Fumarate 120mg, 240mg hard capsules

Adalvo announces DCP approval for Enzalutamide Soft Gel capsules

Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in the treatment of Psoriatic Arthritis and Psoriasis, and currently represents one of the few comfortable and compliant oral treatments for this disease.

Adalvo announces successful Pivotal BE outcome of Apremilast

Adalvo is a B2B pharmaceutical company that helps its partners become bigger, better and smarter in the dynamic pharmaceutical sector. The company provides unique, customized solutions that challenge the status quo, and help partners achieve their business goals.

Fueled by a passion for relentless commitment to the customer network it serves

Adalvo

Fueled by a passion for relentless commitment to the customer network it serves

Adalvo News

Share